KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $673.3 million.

  • Takeda Pharmaceutical's Net Income towards Common Stockholders fell 957.19% to $673.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 billion, marking a year-over-year increase of 4445.12%. This contributed to the annual value of $708.5 million for FY2025, which is 2907.44% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Net Income towards Common Stockholders of $673.3 million as of Q4 2025, which was down 957.19% from $4.7 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Net Income towards Common Stockholders high stood at $4.7 billion for Q3 2025, and its period low was -$97.7 million during Q1 2022.
  • Its 5-year average for Net Income towards Common Stockholders is $1.3 billion, with a median of $827.6 million in 2022.
  • In the last 5 years, Takeda Pharmaceutical's Net Income towards Common Stockholders skyrocketed by 1166003.88% in 2021 and then tumbled by 10524.86% in 2022.
  • Takeda Pharmaceutical's Net Income towards Common Stockholders (Quarter) stood at $508.2 million in 2021, then skyrocketed by 65.92% to $843.2 million in 2022, then increased by 27.73% to $1.1 billion in 2023, then plummeted by 30.86% to $744.6 million in 2024, then dropped by 9.57% to $673.3 million in 2025.
  • Its Net Income towards Common Stockholders was $673.3 million in Q4 2025, compared to $4.7 billion in Q3 2025 and $1.5 billion in Q2 2025.